Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
CervoMed Inc. (CRVO) P/E ratio
CervoMed Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 20.5× (October 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 20.5×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRLA Quince Therapeutics, Inc. compare | n/m |
| CRVO CervoMed Inc. | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| EDSA Edesa Biotech, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| BCTX BRIACELL THERAP compare | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)